REG - Frontier IP Group - Trading Update
RNS Number : 5730TFrontier IP Group plc21 March 2019The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
21 March 2019
Frontier IP Group Plc
("Frontier IP" or the "Group")
Trading update
Frontier IP, a specialist in commercialising university intellectual property, is pleased to provide an update on trading for the year ending 30 June 2019.
The Group has enjoyed a strong first half to the financial year and since the beginning of 2019 there have been a number of positive portfolio updates as previously announced by the Group. In addition, Frontier IP has earlier today announced that Exscientia, a world leader in AI-driven drug discovery, has secured a significant trade deal with Celgene Corporation. This, combined with other progress Exscientia is making, is expected to result in a substantial uplift in Frontier IP's book value for its holding.
Whilst it is not possible for the Board to be certain on what the overall portfolio valuation will be at 30 June 2019 and progress of early and development stage businesses that constitute Frontier IP's portfolio is inherently uncertain, based on the trading for the year to date and the outlook for the remainder of the financial year the Board anticipates that the outcome for the year ending 30 June 2019 will be ahead of management expectations.
The Group will be releasing its interim results for the six months to 31 December 2018 by end of March 2019.
ENQUIRIES
Frontier IP Group Plc
T: 0131 240 1251
Neil Crabb, Chief Executive Officer
Andrew Johnson, Communications & Investor Relations
M: 07464 546 025
Allenby Capital Limited (Nominated Adviser and Broker)
T: 0203 328 5656
Nick Athanas
Nicholas Chambers
ABOUT FRONTIER IP: www.frontierip.co.uk
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDTSTUAAKRKNAOURR
Recent news on Frontier IP
See all newsRCS - Frontier IP Group - TVG to collaborate with The Pirbright Institute
AnnouncementRCS - Frontier IP Group - Frontier IP announces stake in DiaGen
AnnouncementREG - Frontier IP Group - Holding(s) in Company
AnnouncementREG - Frontier IP Group - Appointment of Chief Financial Officer
AnnouncementREG - Frontier IP Group - Holding(s) in Company
Announcement